Status:

COMPLETED

Evaluation of Atuna Racemosa Toxicity

Lead Sponsor:

Mayo Clinic

Conditions:

Bacterial Infections

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

For thousands of years people in the South Pacific have used Atuna racemosa extract as a topical anti-inflammatory. We, the researchers at the Mayo Clinic, have shown this extract to also have antibac...

Eligibility Criteria

Inclusion

  • The subjects will be 20 healthy male and non-pregnant, non-lactating, female volunteers of ages 18 - 65. No subject will be excluded based on minority status.

Exclusion

    Key Trial Info

    Start Date :

    April 1 2006

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    November 1 2007

    Estimated Enrollment :

    20 Patients enrolled

    Trial Details

    Trial ID

    NCT00318344

    Start Date

    April 1 2006

    End Date

    November 1 2007

    Last Update

    February 2 2010

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Mayo Clinic

    Rochester, Minnesota, United States, 55905

    Evaluation of Atuna Racemosa Toxicity | DecenTrialz